Table 1 Clinical demographic information for patients.

From: Circulating stromal cells in resectable pancreatic cancer correlates to pathological stage and predicts for poor clinical outcomes

  (n = 63)
Age (Median) 66.6
Age IQR, Range 61–73.5, 45–90
Gender
 Male 37(58%)
 Female 26 (41%)
Histology
 Pancreatic adenocarcinoma 62 (98%)
 Acinar adenocarcinoma 1 (2%)
Pathological stage
 I 18 (29%)
 II 12 (19%)
 III 7 (11%)
 IV 19 (30%)
 Unknown 7 (11%)
Resectability
 Resectable 20 (32%)
 Borderline resectable 27 (43%)
 Locally advanced 6 (9%)
 Metastatic 10 (15%)
 CAMLs present 58 (95%)
 Median CAML size 57.5 μm (0–189)
 CTCs present 14 (22%)
Pre-Surgical CA19-9
 Above threshold (≥37 U/mL) 27 (42%)
 Below threshold (<37 U/mL) 31 (49%)
Unknown 5 (7%)
Pre-surgical CEA
 Above threshold (≥5 ng/mL) 10(16%)
 Below threshold (<5 ng/mL) 44 (69%)
 Unknown 9 (14%)
 Neoadjuvant chemo 54 (85%)
 Adjuvant chemotherapy 40 (63%)
 Radiation therapy 41 (65%)
 Surgical resection 37 (58%)
Resection margin
Positive 3 (4.5%)
Negative 38 (57%)